Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

1.1K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

157
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
157
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

1.4K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026
Same author

Long-Term Outcomes in Stiff Person Spectrum Disorder.

European journal of neurology·2026
Same author

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice.

Annals of clinical and translational neurology·2026
Same author

Population-Based Epidemiology of Autoimmune Seizures and Epilepsies.

Annals of neurology·2026
Same author

Paraneoplastic neurologic disorders and neurologic complications of immune checkpoint inhibitors.

Handbook of clinical neurology·2026
Same author

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.

Blood cancer journal·2025

Related Experiment Video

Updated: Jun 18, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K

Paraneoplastic Neurologic Disorders.

Anastasia Zekeridou

    Continuum (Minneapolis, Minn.)
    |August 1, 2024
    PubMed
    Summary

    Paraneoplastic neurologic syndromes and autoimmune conditions are increasingly recognized with immune checkpoint inhibitor (ICI) cancer immunotherapy. Neural antibodies aid diagnosis, prognosis, and treatment of these complex neurological disorders.

    Area of Science:

    • Neurology
    • Immunology
    • Oncology

    Background:

    • Paraneoplastic neurologic syndromes (PNS) are associated with cancer and mediated by immune responses.
    • Neural antibodies are crucial for diagnosing PNS, understanding pathophysiology, and guiding treatment.
    • Immune checkpoint inhibitors (ICIs) have increased the incidence of ICI-related neurologic autoimmunity.

    Purpose of the Study:

    • To review the clinical features, neural antibody associations, and oncologic aspects of PNS.
    • To discuss the impact of ICI therapy on neurologic autoimmunity.
    • To highlight the diagnostic and prognostic value of neural antibodies.

    Main Methods:

    • Literature review of paraneoplastic neurologic syndromes and immune checkpoint inhibitor-associated autoimmunity.

    More Related Videos

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
    09:33

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

    Published on: August 25, 2023

    1.1K
    A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
    08:59

    A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

    Published on: January 5, 2017

    10.6K

    Related Experiment Videos

    Last Updated: Jun 18, 2025

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    1.9K
    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
    09:33

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

    Published on: August 25, 2023

    1.1K
    A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
    08:59

    A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

    Published on: January 5, 2017

    10.6K
  • Analysis of neural antibody associations and their clinical significance.
  • Discussion of diagnostic criteria and updated scoring systems for PNS.

    • Main Results:

    • Neural antibody discovery has significantly improved PNS diagnosis and understanding.
    • Antibodies targeting extracellular proteins are pathogenic, while intracellular targets indicate a T-cell response.
    • ICI therapy is associated with distinct phenotypes of immune-mediated neurologic complications.

    Conclusions:

    • Neural antibodies are vital biomarkers for PNS, aiding diagnosis, cancer screening, and prognosis.
    • Early recognition and treatment of ICI-related neurologic autoimmunity are essential for improved patient outcomes.
    • Clinical suspicion of PNS warrants cancer screening and treatment, irrespective of antibody presence.